Loading...

Actinogen Medical

DB:3AC
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3AC
DB
A$59M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
  • Actinogen Medical has significant price volatility in the past 3 months.
3AC Share Price and Events
7 Day Returns
3.7%
DB:3AC
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
21.7%
DB:3AC
-10.2%
DE Biotechs
-6%
DE Market
3AC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Actinogen Medical (3AC) 3.7% -3.4% -3.4% 21.7% -54.8% 75%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 3AC outperformed the Biotechs industry which returned -10.2% over the past year.
  • 3AC outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
3AC
Industry
5yr Volatility vs Market

Value

 Is Actinogen Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Actinogen Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.028.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Actinogen Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Actinogen Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3AC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:ACW Share Price ** ASX (2019-04-18) in AUD A$0.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Actinogen Medical.

DB:3AC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ACW Share Price ÷ EPS (both in AUD)

= 0.05 ÷ -0.01

-5.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Actinogen Medical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Actinogen Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Actinogen Medical's expected growth come at a high price?
Raw Data
DB:3AC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
15.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Actinogen Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Actinogen Medical's assets?
Raw Data
DB:3AC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:ACW Share Price * ASX (2019-04-18) in AUD A$0.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:3AC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ACW Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.02

3.25x

* Primary Listing of Actinogen Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Actinogen Medical is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Actinogen Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Actinogen Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Actinogen Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Actinogen Medical expected to grow at an attractive rate?
  • Unable to compare Actinogen Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Actinogen Medical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Actinogen Medical's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:3AC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3AC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 15.9%
DB:3AC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3AC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3AC Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-06-30 3 -8 1
2019-06-30 4 -10 1
DB:3AC Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -9 -10
2018-09-30 3 -8 -8
2018-06-30 3 -8 -6
2018-03-31 2 -6 -6
2017-12-31 2 -4 -5
2017-09-30 1 -3 -4
2017-06-30 1 -1 -3
2017-03-31 2 -2 -4
2016-12-31 3 -2 -4
2016-09-30 3 -4 -4
2016-06-30 4 -5 -4
2016-03-31 3 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Actinogen Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Actinogen Medical's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3AC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Actinogen Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3AC Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-06-30 -0.01 -0.01 -0.01 1.00
2019-06-30 -0.01 -0.01 -0.01 1.00
DB:3AC Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01
2016-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Actinogen Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Actinogen Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Actinogen Medical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Actinogen Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Actinogen Medical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Actinogen Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Actinogen Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Actinogen Medical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Actinogen Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Actinogen Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3AC Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.16 -9.74 1.60 10.98
2018-09-30 3.23 -7.98 1.53 9.36
2018-06-30 3.30 -6.23 1.46 7.74
2018-03-31 2.43 -5.60 1.35 6.33
2017-12-31 1.55 -4.97 1.23 4.92
2017-09-30 1.49 -4.08 1.14 4.05
2017-06-30 1.42 -3.19 1.05 3.19
2017-03-31 2.02 -3.76 1.13 4.25
2016-12-31 2.62 -4.32 1.21 5.32
2016-09-30 3.29 -3.98 1.41 5.47
2016-06-30 3.95 -3.63 1.60 5.61
2016-03-31 2.70 -4.50 2.08 4.75
2015-12-31 1.44 -5.37 2.55 3.90
2015-09-30 0.80 -5.40 2.57 3.33
2015-06-30 0.15 -5.43 2.60 2.76
2015-03-31 0.14 -3.47 1.81 1.68
2014-12-31 0.14 -1.51 1.03 0.59
2014-09-30 0.16 -0.97 0.70 0.41
2014-06-30 0.18 -0.44 0.37 0.22
2014-03-31 0.18 -0.37 0.33 0.19
2013-12-31 0.17 -0.30 0.29 0.16
2013-09-30 0.23 -0.23 0.23 0.22
2013-06-30 0.30 -0.16 0.17 0.29
2013-03-31 0.30 -0.35 0.30 0.25
2012-12-31 0.31 -0.54 0.43 0.21
2012-09-30 0.18 -1.04 0.57 0.11
2012-06-30 0.05 -1.53 0.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Actinogen Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Actinogen Medical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Actinogen Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Actinogen Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Actinogen Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Actinogen Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Actinogen Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Actinogen Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Actinogen Medical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Actinogen Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Actinogen Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Actinogen Medical Company Filings, last reported 3 months ago.

DB:3AC Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 18.21 0.00 15.47
2018-09-30 18.21 0.00 15.47
2018-06-30 17.26 0.00 10.00
2018-03-31 17.26 0.00 10.00
2017-12-31 9.34 0.00 5.51
2017-09-30 9.34 0.00 5.51
2017-06-30 9.37 0.00 3.99
2017-03-31 9.37 0.00 3.99
2016-12-31 10.28 0.00 5.68
2016-09-30 10.28 0.00 5.68
2016-06-30 12.13 0.00 4.78
2016-03-31 12.13 0.00 4.78
2015-12-31 14.44 0.00 7.87
2015-09-30 14.44 0.00 7.87
2015-06-30 15.36 0.00 9.81
2015-03-31 15.36 0.00 9.81
2014-12-31 8.34 0.00 2.05
2014-09-30 8.34 0.00 2.05
2014-06-30 1.21 0.00 1.13
2014-03-31 1.21 0.00 1.13
2013-12-31 1.47 0.00 1.35
2013-09-30 1.47 0.00 1.35
2013-06-30 0.19 0.00 0.11
2013-03-31 0.19 0.00 0.11
2012-12-31 0.35 0.00 0.30
2012-09-30 0.35 0.00 0.30
2012-06-30 0.35 0.00 0.20
  • Actinogen Medical has no debt.
  • Actinogen Medical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Actinogen Medical has sufficient cash runway for 1.8 years based on current free cash flow.
  • Actinogen Medical has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 28.8% each year.
X
Financial health checks
We assess Actinogen Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Actinogen Medical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Actinogen Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Actinogen Medical dividends.
If you bought €2,000 of Actinogen Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Actinogen Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Actinogen Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3AC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3AC Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Actinogen Medical has not reported any payouts.
  • Unable to verify if Actinogen Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Actinogen Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Actinogen Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Actinogen Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Actinogen Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Actinogen Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Actinogen Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Ketelbey
COMPENSATION A$424,206
TENURE AS CEO 4.3 years
CEO Bio

Dr. John William Ketelbey, also known as Bill, MBBCH, FFPM, MBA, GAICD, has been the Chief Executive Officer and Managing Director at Actinogen Medical Limited since December 18, 2014. Dr. Ketelbey is responsible for overseeing the development and commercialisation of XanamemTM for the treatment of Alzheimer's disease and mild cognitive impairment. Dr. Ketelbey has specialist expertise in pharmaceutical medicine including in particular experience in neurological drugs. At Pfizer, Dr. Ketelbey was In Charge of the Australian/New Zealand development and involved in the launch and commercialisation of AriceptTM (donepezil), an acetylcholinesterase inhibitor, the market leading Alzheimer's disease therapy locally and globally. He was involved in developing monoclonal antibodies directed at amyloid plaques, a hallmark of Alzheimer's. Dr. Ketelbey served as Regional Vice President of Medical Affairs for Pfizer's Primary Care Business Unit for Australia and New Zealand, Japan, Canada, Korea and Country Medical Director for Pfizer Australia and New Zealand. Dr. Ketelbey serves as a Director of Actinogen Medical Limited. Dr. Ketelbey is a highly experienced and successful healthcare and pharmaceutical sector professional, with 30 years' experience in the industry, including senior medical and management roles with global pharmaceutical giant, Pfizer. Dr. Ketelbey is a qualified Medical Doctor from the University of the Witwatersrand, South Africa and an MBA graduate from Macquarie University.

CEO Compensation
  • Bill's compensation has been consistent with company performance over the past year.
  • Bill's remuneration is about average for companies of similar size in Germany.
Management Team

Bill Ketelbey

TITLE
MD, CEO & Director
COMPENSATION
A$424K
TENURE
4.3 yrs

Peter Webse

TITLE
Company Secretary
AGE
55
TENURE
5.5 yrs
Board of Directors Tenure

Average tenure and age of the Actinogen Medical board of directors in years:

4.1
Average Tenure
65.5
Average Age
  • The tenure for the Actinogen Medical board of directors is about average.
Board of Directors

Geoff Brooke

TITLE
Non-Executive Chairman
COMPENSATION
A$222K
AGE
62
TENURE
2.1 yrs

Bill Ketelbey

TITLE
MD, CEO & Director
COMPENSATION
A$424K
TENURE
4.3 yrs

Craig Ritchie

TITLE
Chairman of Xanamem Clinical Advisory Board
TENURE
4.1 yrs

Colin Masters

TITLE
Member of Xanamem Clinical Advisory Board
AGE
71
TENURE
4.1 yrs

Jeff Cummings

TITLE
Member of Xanamem Clinical Advisory Board
TENURE
4.1 yrs

George Morstyn

TITLE
Non-Executive Director
COMPENSATION
A$38K
AGE
68
TENURE
1.3 yrs

Malcolm McComas

TITLE
Non-Executive Director
AGE
63
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Mar 19 Sell BVF Partners LP Company 07. Dec 18 07. Dec 18 -8,777,268 €0.02 €-185,691
21. Mar 19 Buy BVF Partners LP Company 09. Jul 18 05. Dec 18 20,522,458 €0.03 €574,501
21. Mar 19 Buy BVF Partners LP Company 18. Jul 18 18. Jul 18 7,200,000 €0.03 €228,360
13. Mar 19 Buy FIL Limited Company 29. Nov 18 11. Mar 19 56,375,471 €0.04 €2,081,507
15. Oct 18 Buy Australian Ethical Investment Ltd Company 02. Jul 18 12. Oct 18 37,323,117 €0.03 €936,949
05. Jun 18 Buy George Morstyn Individual 01. Jun 18 01. Jun 18 200,000 €0.03 €6,662
31. May 18 Buy BVF Partners LP Company 28. May 18 28. May 18 187,122,994 €0.03 €6,075,073
X
Management checks
We assess Actinogen Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Actinogen Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer’s disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer’s disease; and XanADu, a Phase II double-blind, 12-week, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer’s disease. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia.

Details
Name: Actinogen Medical Limited
3AC
Exchange: DB
Founded:
A$37,577,467
1,119,231,320
Website: http://www.actinogen.com.au
Address: Actinogen Medical Limited
109 Pitt Street,
Suite 901,
Sydney,
New South Wales, 2000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ACW Ordinary Shares Australian Securities Exchange AU AUD 16. Oct 2007
OTCPK ATGG.F Ordinary Shares Pink Sheets LLC US USD 16. Oct 2007
DB 3AC Ordinary Shares Deutsche Boerse AG DE EUR 16. Oct 2007
CHIA ACW Ordinary Shares Chi-X Australia AU AUD 16. Oct 2007
Number of employees
Current staff
Staff numbers
0
Actinogen Medical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:39
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/02/22
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.